glp 1 oral support FDA UPDATE: A new GLP-1 medication has been approved 🚨 For the first time, patients now have an FDA-approved oral option for medical weight management—expanding choices beyond injectable treatments. This breakthrough GLP-1 Oral Solution & Peptide

Unadjusted analysis found relatively higher (4 and 5.4% additional) weight loss, HbA1c (0.4% additional) reduction, and fewer gastrointestinal side effects with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg [25]

Incretin-based therapies and diabetic retinopathy: real-world evidence in Older U.S

Currently, in 2026, there isnt strong clinical data to suggest one is significantly more likely to cause anxiety than the other

This oncologic safety concern is magnified by the fact that many cancers remain clinically silent during their early developmental stages

Distinguishing Normal Adaptation From a Side Effect That Needs Medical Attention A lighter or delayed period during the first 812 weeks of tirzepatide is typically expected and usually harmless